Freezing Shows Promise in Treating Prostate Cancer

Publication
Article
OncologyONCOLOGY Vol 9 No 6
Volume 9
Issue 6

By literally freezing prostate cancer cells to death, radiologists can effectively treat prostate cancer in some patients while reducing complication rates, preliminary results of a study show. The new procedure, trans- rectal ultrasound-guided

By literally freezing prostate cancer cells to death, radiologistscan effectively treat prostate cancer in some patients while reducingcomplication rates, preliminary results of a study show. The newprocedure, trans- rectal ultrasound-guided cryoablation, alsocosts less than traditional prostate cancer treatments, the studyindicates.

Of the 310 men treated with the technique so far, 90% have hadnegative biopsies, said Dr. Duke Bahn, chair of the Departmentof Radiology at Crittenton Hospital in Rochester, Michigan. Follow-upof these patients ranged from 3 months to 2 years, Dr. Bahn toldthe American Roentgen Ray Society at its annual meeting in Washington,D.C.

Patients with cancer confined to the prostate gland or those whosecancer has spread near the gland are candidates for the freezingprocedure, said Dr. Bahn. Probes are inserted through small skinpunctures into the prostate gland. Liquid nitrogen is circulatedthrough the probes and the entire prostate is frozen. When theprostate thaws, the cells rupture and die, he said. "Thefreezing process is carefully monitored by high resolution ultrasoundto avoid injuries to adjacent organs," said Dr. Bahn. Patientsusually are only in the hospital overnight, and they can returnto their normal routine in about 2 weeks.

The cost of cryoablation is about one-third to one-half that ofsurgery or radiation therapy, Dr. Bahn noted. Complication ratesappear to be much lower than rates associated with surgery. Forexample, incontinence occurs in at least 30% of patients who undergosurgery. "Our incontinence rate is only 1%," said Dr.Bahn.

The cryoablation procedure can be repeated if it fails, said Dr.Bahn. Patients also can choose to undergo radiation therapy orsurgery if cryoablation proves ineffective, he added.

"We are very optimistic about this procedure," saidDr. Bahn. However, he cautioned, long-term clinical trials needto be done to determine whether this treatment increases overallsurvival. Transrectal ultrasound-guided cryoablation is availablein about 100 institutions across the United States.

Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Considering which non–muscle-invasive bladder cancer cases may be cured by surgery alone may help mitigate overtreatment in this patient group.
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Related Content